Miami, FL, United States of America

Assuan Lens

This inventor holds 1 USPTO granted patent. Top assignee: University of Miami. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Assuan Lens. Retrieved from https://idiyas.com/inventor/assuan-lens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Assuan Lens: Advancing Cannabidiol Nanodrug Formulations

Introduction

Assuan Lens is an inventor based in Miami, Florida, whose patent work focuses on cannabidiol formulations and potential therapeutic applications. His disclosed invention explores topical nanoparticulate cannabidiol formulations and their possible use in treating autoimmune diseases and disorders, including alopecia areata.

Latest Patents

Lens is associated with 1 patent: “Cannabidiol Nanodrug Formulations and Methods for Use of the Same.” The patent describes topical cannabidiol formulations, methods for preparing them, and their use in treating autoimmune conditions. The disclosed formulations include nanoparticulate cannabidiol.

Career Highlights

Lens’s listed patent work is connected with the University of Miami. The invention reflects research into formulation approaches that may support the topical delivery of cannabidiol for therapeutic purposes.

Collaborations

Lens’s listed coworkers include Nadia Peyravian and Sylvia Daunert. Their names are associated with the research and patent context provided for this invention.

Conclusion

Assuan Lens’s patent work highlights an approach to topical cannabidiol delivery and its potential application in autoimmune disease research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…